Product Description
a 1:1 protein mixture of two human anti-RABV MAbs (CR57/CR4098)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Crucell Holland BV
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Rabies
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| RAB-M-A008 | P2 |
Completed |
Rabies |
2012-10-01 |
2019-03-19 |
Treatments |
|
| RAB-M-A004 | P2 |
Completed |
Rabies |
2008-10-01 |
2019-03-18 |
Treatments |
|
| RAB-M-A003 | P2 |
Completed |
Rabies |
2008-07-01 |
2019-03-18 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2006 |
PubMed |
Porfimer. |
|
12/01/2023 |
PubMed |
Comparative assessment of the copy number of satellite repeats in the genome of Triticeae species. |